touchRESPIRATORY joins Professor Frédéric de Blay (University Hospital of Strasbourg, Strasbourg, France) at EAACI 2021 to discuss the results of a phase 2, randomised, double-blind, placebo-controlled study of anti-Fel d 1 monoclonal antibodies in reducing the rate of early asthma responses, chest symptoms and rescue medication use in cat-allergic subjects with mild asthma for up to 3 months following a controlled cat allergen challenge.
1. Could you give us a brief overview of the health burden of cat allergy? (00:29-01:57)
2. What are anti-Fel d 1 monoclonal antibodies and what is the rationale for use in combating cat allergy? (01:57 -02:43)
3. What were the aims and design of the Phase 2 study? (02:43-04:00)
4. What were the efficacy and safety findings of the study? (04:00-05:00)
5. What will be the next step in the clinical development of anti-Fel d 1 monoclonal antibodies? (05:00-06:04)
Disclosures: Professor Frédéric de Blay has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 EAACI Annual Meeting.
Share this Video
Related Videos In Allergy
Ozge Can Bostan, EAACI 2022: Low Dose Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]
Ronald Strauss: Intranasal Corticosteroids in the Prevention and Treatment of COVID-19
It was a pleasure to talk with Dr Ronald Strauss (Cleveland Allergy and Asthma Center; Case Western Reserve University Medical School, Cleveland, OH, USA) around his article exploring the use of intranasal corticosteroids in the prevention and/ or treatment of COVID-19. Questions What is known about the major ports of entry for the SARS-CoV-2 virus? […]
Ronald Strauss, AAAAI 2022: the Impact of Eosinophilia on COVID-19 Outcomes
touchRESPIRATORY were delighted to talk with Dr Ronald Strauss (Cleveland Allergy and Asthma Center; Case Western Reserve University Medical School, Cleveland, OH, USA) around his analysis of the association of eosinophilia with improved COVID-19 outcomes in patients treated with inhaled corticosteroids. The abstract ‘Eosinophilia is Associated with Improved COVID-19 Outcomes in Patients Treated with Inhaled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!